Intuitive Surgical's da Vinci system went essentially unchallenged for two decades, holding 71% of the surgical robotics market with more than 10,670 systems installed worldwide, but December 2025 marked a genuine turning point: both Medtronic's Hugo and CMR Surgical's Versius Plus received FDA clearance in the same month, finally giving hospitals credible, well-funded alternatives. Before comparing the three systems, it's worth being direct about what AI has and hasn't actually changed here: none of these robots operate autonomously. Every one remains a surgeon-controlled tool, with AI assisting specific tasks rather than making independent decisions in the operating room.
da Vinci: The Incumbent With a 71% Market Share
Intuitive Surgical's dominance remains substantial even as competition arrives: the company generated $8.4 billion in revenue in 2025, has placed more than 10,670 da Vinci systems in hospitals globally, and those systems have been used in over 12 million procedures. In the fourth quarter of 2025 alone, Intuitive shipped 532 new systems, including 303 units of its newest da Vinci 5 platform — continued strong demand even as rivals gain regulatory clearance. da Vinci 5 represents a genuine technical leap for the platform, with roughly 10,000 times the computing power of earlier generations, enabling real-time surgical risk assessment and automated suturing of simple closures. Pricing reflects the platform's premium positioning: the older da Vinci Xi runs $2.5 million to $3 million, while da Vinci 5 costs $2.8 million to $3.5 million, before annual maintenance, service, and disposable instrument costs that typically add another $100,000 to $300,000 per year.
Medtronic Hugo: Finally FDA Cleared
Medtronic's Hugo RAS system received FDA clearance for urologic procedures in December 2025, a genuine milestone after years of development, with the company now pursuing additional clearances in general surgery and gynecology. Hugo uses a modular, cart-based design rather than da Vinci's fixed central tower, giving hospitals more flexibility in operating room layout, faster setup between cases, and a smaller physical footprint. Pricing sits meaningfully below da Vinci, at $1.5 million to $2 million. Industry analysts expect Hugo's early adoption to come disproportionately from surgeons and institutions already loyal to Medtronic's broader surgical instrument portfolio, academic institutions seeking a second robotic platform for research and training diversity, and surgeons who simply never adopted an Intuitive system in the first place — rather than hospitals abandoning existing da Vinci installations.
CMR Surgical Versius: The Subscription Model
CMR Surgical, a Cambridge, UK-based company valued at $3 billion in its 2021 funding round, secured FDA clearance for its Versius Plus system in the same December 2025 window as Medtronic's Hugo clearance — a genuine inflection point for the whole competitive landscape arriving all at once. Versius's core differentiation is portability: a modular design specifically built to move between operating rooms, or even between hospitals, more easily than da Vinci's fixed installation. Its business model is the most distinctive of the three: rather than a multimillion-dollar upfront purchase, Versius uses per-procedure leasing starting around $1,200 per case, with no large capital outlay required — a genuinely different financial structure that removes the biggest adoption barrier for smaller hospitals and outpatient surgical centers that could never justify a $2-3.5 million capital purchase. CMR's installed base by 2026 spans UK NHS hospitals, India, continental Europe, and select Latin American markets.
How Much Has AI Actually Changed Surgery?
This is worth answering plainly: current surgical robots, across all three systems, remain surgeon-controlled tools. The surgeon operates from a console using hand and foot inputs, gaining real precision benefits — tremor filtration and up to 10x magnification — but the robot itself makes no independent decisions during the procedure. What AI has genuinely added is task-specific assistance layered on top of that surgeon-controlled foundation: real-time risk assessment, automated suturing of simple wound closures (not full procedures), and AI-powered navigation and vision-based tissue classification increasingly built into newer systems' workflows. A useful comparison point from outside this specific trio: Stryker's orthopedic-focused Mako system uses AI primarily for preoperative planning — CT-based 3D modeling of implant positioning — with the robot then physically constraining the surgeon's instrument to the pre-planned cuts during the actual procedure, a deliberate safety boundary rather than autonomous operation. Industry analysis expects AI to expand into intraoperative decision support and complication prediction within roughly five years, but genuine surgical autonomy remains, by most credible accounts, decades away, constrained as much by regulatory and safety requirements as by the underlying technology.
The Real 2026 Competitive Strategy
The most important strategic insight for 2026 isn't about out-competing da Vinci feature-for-feature — it's about where the new entrants are actually choosing to compete. Hospitals with an established da Vinci program have already invested heavily in Intuitive's training pipeline, instrument ecosystem, and service contracts, making a full platform switch expensive and disruptive regardless of a competitor's technical merits. Industry analysts specifically identify new sites of care — hospitals and surgical centers that haven't adopted any robotic surgery platform at all — as the real 2026 battleground, with Hugo and Versius targeting that underserved segment rather than attempting to displace entrenched da Vinci installations directly.
Surgical Robot Comparison at a Glance
| System | Price | Design | Market position (2026) |
|---|---|---|---|
| Intuitive da Vinci 5/Xi | $2.5M-$3.5M | Fixed central tower | 71% market share, 10,670+ installed systems |
| Medtronic Hugo | $1.5M-$2M | Modular, cart-based | FDA-cleared Dec 2025 for urologic procedures |
| CMR Surgical Versius | ~$1,200/case (leasing, no upfront capital) | Modular, portable | FDA-cleared Dec 2025 (Versius Plus) |
Frequently Asked Questions
Do surgical robots operate autonomously?
No. Current surgical robots, including da Vinci, Hugo, and Versius, remain fully surgeon-controlled. The surgeon operates from a console with hand and foot inputs, and the robot provides precision benefits like tremor filtration and magnification, but makes no independent decisions during the procedure.
Why did Medtronic and CMR Surgical both get FDA clearance in the same month?
Both Medtronic's Hugo and CMR Surgical's Versius Plus received FDA clearance in December 2025, marking what industry analysts describe as a genuine inflection point for the surgical robotics market after Intuitive Surgical's roughly two-decade run without credible, well-capitalized competition.
How is CMR Surgical's Versius priced differently from da Vinci and Hugo?
Versius uses a per-procedure leasing model starting around $1,200 per case, requiring no large upfront capital purchase, unlike da Vinci ($2.5-3.5 million) and Hugo ($1.5-2 million), which are sold as capital equipment purchases.
Will da Vinci lose market share to Hugo and Versius?
Analysts expect new competitors to primarily target hospitals without any existing robotic surgery program, rather than displacing da Vinci at hospitals already invested in Intuitive's training, instruments, and service ecosystem, since switching platforms is costly and disruptive regardless of a competitor's technical merits.